GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hemogenyx Pharmaceuticals HEMO.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

565.00p

-0.88%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in GBP, from our data supplier.

FY2025

Net income

−£9.8m

FY2016FY2025

Free cash flow

−£3.5m

FY2016FY2025

Shareholders' equity

£1.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit−£588,753−£639,285−£645,681−£2.6m−£283,647−£350,719−£421,817−£348,266−£100,481—
Research and development—£236,722£90,632£403£38£84£21£57,653£14,046£1,619
Operating income−£4.7m−£5.7m−£6.5m£4.0m−£2.5m−£2.2m−£1.7m−£1.6m−£820,976−£519,898
Net income−£9.8m−£5.6m−£6.7m−£4.0m−£5.1m−£2.1m−£1.5m−£1.5m−£2.4m−£519,898
Diluted earnings per share-1.62-1.60-2.28-1.62-2.08-1.92-1.61-1.64-3.24-3.19

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets£4.2m£4.2m£61,059£7.1m£8.5m£2.7m£1.0m£2.3m£2.4m£1.0m
Cash and short-term investments£1.6m£159,265£12,476£2.5m£6.8m£1.8m£498,679£1.8m£1.9m£1.0m
Total liabilities£3.0m£3.4m£33,249£3.8m£352,841£1.8m£1.4m£1.3m£263,685£143,695
Debt£2.0m£2.6m£29,459£3.4m£10,152£1.6m£1.3m£1.2m—£301,056
Shareholders' equity£1.2m£897,514£28,187£3.3m£8.2m£890,839−£346,518£959,166£2.1m£903,708
Shares outstanding6m4m3m2m2m1m1m1m1m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−£3.4m−£4.1m−£6.1m−£2.9m−£2.6m−£1.8m−£1.2m−£1.4m−£452,979−£278,146
Capital spending−£3,921−£13,284−£117,285−£428,945−£817,998−£173,047−£11,918−£24,589−£64,257−£189
Free cash flow−£3.5m−£4.1m−£6.2m−£3.3m−£3.4m−£2.0m−£1.2m−£1.4m−£517,236−£278,335

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023
Gross profit−£246,178−£274,970−£313,783−£317,600−£643,370—−£325,772—
Operating income−£7.5m−£2.1m−£2.6m−£2.7m−£2,691−£1,346−£2.2m−£1,125
Net income−£6.6m−£4.8m−£5.0m−£2.8m−£2,812−£1,406−£2.4m−£1,185
Diluted earnings per share-1.02-0.79-0.83-0.80-0.00-0.00-0.81-0.00
Cash from operations−£1.0m—−£3.0m−£1.0m−£2.0m———
Total assets£6.9m£4.2m£3.1m£4.2m£6.1m£6.1m£6.1m£6.1m
Cash and short-term investments£4.6m£1.6m£226,727£159,265£1.6m£1.6m£1.2m£1.2m
Debt£491,050£442,416£413,515£423,673£255,604£255,604£546,168£273,084
Shareholders' equity£4.3m£1.2m−£500,147£897,514£3.1m£3.1m£2.8m£2.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income—16.7%93.7%
Net income34.9%36.2%108.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-3.5-1.6-2.6-2.1-2.3-8.3-2.0-2.1-1.3-1.9

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 400-to-1 reverse split · 13 Dec 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.